These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 4028622)

  • 1. Pharmacokinetics of transdermally delivered clonidine.
    MacGregor TR; Matzek KM; Keirns JJ; van Wayjen RG; van den Ende A; van Tol RG
    Clin Pharmacol Ther; 1985 Sep; 38(3):278-84. PubMed ID: 4028622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of transdermally administered clonidine.
    Arndts D; Arndts K
    Eur J Clin Pharmacol; 1984; 26(1):79-85. PubMed ID: 6714294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of clonidine.
    Lowenthal DT; Matzek KM; MacGregor TR
    Clin Pharmacokinet; 1988 May; 14(5):287-310. PubMed ID: 3293868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and side-effects of clonidine.
    Keränen A; Nykänen S; Taskinen J
    Eur J Clin Pharmacol; 1978 May; 13(2):97-101. PubMed ID: 658114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of a new transdermal clonidine, M-5041T, in healthy subjects.
    Fujimura A; Ebihara A; Shiga T; Kumagai Y; Ohashi K; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1993 Dec; 33(12):1192-200. PubMed ID: 8126254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of application site of a new transdermal clonidine, M-5041T, on its pharmacokinetics and pharmacodynamics in healthy subjects.
    Ebihara A; Fujimura A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1993 Dec; 33(12):1188-91. PubMed ID: 8126253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of the contribution of clonidine metabolised from alinidine to the cardiovascular effects of alinidine.
    Harron DW; Arndts D; Finch M; Shanks RG
    Br J Clin Pharmacol; 1983 Oct; 16(4):451-5. PubMed ID: 6626441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal clonidine application: long-term results in essential hypertension.
    Groth H; Vetter H; Knüsel J; Foerster E; Siegenthaler W; Vetter W
    Klin Wochenschr; 1984 Oct; 62(19):925-30. PubMed ID: 6503214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of nitroglycerin and clonidine delivered by the transdermal route.
    Shaw JE
    Am Heart J; 1984 Jul; 108(1):217-23. PubMed ID: 6428208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alinidine pharmacokinetics following acute and chronic dosing.
    Harron DW; Arndts D; Shanks RG
    Br J Clin Pharmacol; 1982 Jun; 13(6):821-7. PubMed ID: 7093113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo characterization of a newly developed clonidine transdermal patch for treatment of attention deficit hyperactivity disorder in children.
    Ke GM; Wang L; Xue HY; Lu WL; Zhang X; Zhang Q; Guo HY
    Biol Pharm Bull; 2005 Feb; 28(2):305-10. PubMed ID: 15684489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New aspects of the clinical pharmacology of clonidine.
    Arndts D
    Chest; 1983 Feb; 83(2 Suppl):397-400. PubMed ID: 6822136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects.
    Fujimura A; Ebihara A; Ohashi K; Shiga T; Kumagai Y; Nakashima H; Kotegawa T
    J Clin Pharmacol; 1994 Mar; 34(3):260-5. PubMed ID: 8021335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral sustained release clonidine in humans.
    MacGregor TR; Relihan GL; Keirns JJ
    Arzneimittelforschung; 1985; 35(1A):440-6. PubMed ID: 4039184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proof of the linearity of the pharmacokinetics of alinidine in man.
    Arndts D; Warnkross H; Rominger KL; Justus H
    Eur J Clin Pharmacol; 1981; 21(3):201-7. PubMed ID: 7318879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man.
    Arndts D; Doevendans J; Kirsten R; Heintz B
    Eur J Clin Pharmacol; 1983; 24(1):21-30. PubMed ID: 6832197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic characterisation of transdermal delivery systems.
    Berner B; John VA
    Clin Pharmacokinet; 1994 Feb; 26(2):121-34. PubMed ID: 8162656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and concentration-effect relationships of intervenous and oral clonidine.
    Davies DS; Wing AM; Reid JL; Neill DM; Tippett P; Dollery CT
    Clin Pharmacol Ther; 1977 May; 21(5):593-601. PubMed ID: 870272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients.
    Frisk-Holmberg M; Edlund PO; Paalzow L
    Br J Clin Pharmacol; 1978 Sep; 6(3):227-32. PubMed ID: 687501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of orally administered misoprostol and cimetidine on the steady state pharmacokinetics of diazepam and nordiazepam in human volunteers.
    Lima DR; Santos RM; Werneck E; Andrade GN
    Eur J Drug Metab Pharmacokinet; 1991; 16(3):161-70. PubMed ID: 1814733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.